Cargando…

Esophageal Stricture Caused by ALK-Positive NSCLC Esophageal Metastasis Resolved After a Few Days of Lorlatinib Therapy Without Stent Placement

Detalles Bibliográficos
Autores principales:	Longo, Vito, Catino, Annamaria, Montrone, Michele, Pizzutilo, Pamela, Ugenti, Ippazio, Lacalamita, Rosanna, Del Bene, Gabriella, Pesola, Francesco, Marech, Ilaria, Galetta, Domenico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474242/ https://www.ncbi.nlm.nih.gov/pubmed/34589934 http://dx.doi.org/10.1016/j.jtocrr.2020.100044

Ejemplares similares

Multiple Genetic Alterations as Resistance Mechanism during Second-Line Lorlatinib for Advanced ALK-Rearranged Lung Adenocarcinoma: A Case Report
por: Catino, Annamaria, et al.
Publicado: (2022)

Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib
por: Longo, Vito, et al.
Publicado: (2021)

What Are the Biomarkers for Immunotherapy in SCLC?
por: Longo, Vito, et al.
Publicado: (2021)

Prognostic factors for survival in extensive‐stage small cell lung cancer: An Italian real‐world retrospective analysis of 244 patients treated over the last decade
por: Longo, Vito, et al.
Publicado: (2022)

Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review
por: Montrone, Michele, et al.
Publicado: (2023)

Controversial role of mast cells in NSCLC tumor progression and angiogenesis
por: Longo, Vito, et al.
Publicado: (2022)

Discordance between FISH, IHC, and NGS Analysis of ALK Status in Advanced Non–Small Cell Lung Cancer (NSCLC): a Brief Report of 7 Cases()
por: Scattone, Anna, et al.
Publicado: (2018)

Lorlatinib-Induced Pulmonary Embolism in a Patient With an ALK-Positive NSCLC
por: Toyozawa, Ryo, et al.
Publicado: (2020)

Impact of tobacco control interventions on smoking initiation, cessation, and prevalence: a systematic review
por: Bafunno, Daniela, et al.
Publicado: (2020)

KRAS-Driven Lung Adenocarcinoma and B Cell Infiltration: Novel Insights for Immunotherapy
por: Rosamaria, Pinto, et al.
Publicado: (2019)

A CT-based transfer learning approach to predict NSCLC recurrence: The added-value of peritumoral region
por: Bove, Samantha, et al.
Publicado: (2023)

Informative Power Evaluation of Clinical Parameters to Predict Initial Therapeutic Response in Patients with Advanced Pleural Mesothelioma: A Machine Learning Approach
por: Massafra, Raffaella, et al.
Publicado: (2022)

Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC
por: Yun, Karen M, et al.
Publicado: (2022)

Incidence of Infections and Predictors of Mortality During Checkpoint Inhibitor Immunotherapy in Patients With Advanced Lung Cancer: A Retrospective Cohort Study
por: Bavaro, Davide Fiore, et al.
Publicado: (2021)

Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib
por: Takeyasu, Yuki, et al.
Publicado: (2022)

First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN
por: Hayashi, Hidetoshi, et al.
Publicado: (2023)

Gender Differences and Immunotherapy Outcome in Advanced Lung Cancer
por: Vavalà, Tiziana, et al.
Publicado: (2021)

Safety evaluation of immune checkpoint inhibitors combined with chemotherapy for the treatment of small cell lung cancer: A meta‐analysis of randomized controlled trials
por: Longo, Vito, et al.
Publicado: (2023)

Favourable outcome of coronavirus disease 2019 in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer receiving alectinib
por: Montrone, Michele, et al.
Publicado: (2020)

Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis
por: Hochmair, Maximilian J., et al.
Publicado: (2020)

Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis
por: Liu, Geoffrey, et al.
Publicado: (2023)

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
por: Mizuta, Hayato, et al.
Publicado: (2021)

Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience
por: Rupp, Martin, et al.
Publicado: (2023)

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report
por: Thummalapalli, Rohit, et al.
Publicado: (2023)

A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan
por: Goto, Yasushi, et al.
Publicado: (2023)

Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC
por: Ma, Xiya, et al.
Publicado: (2023)

Successful Use of Esophageal Stent Placement to Treat a Postoperative Esophageal Stricture in a Toddler
por: Gebrail, Rami, et al.
Publicado: (2014)

Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib
por: Gower, Arjan, et al.
Publicado: (2020)

Esophageal Lichen Planus Stricture
por: Zamani, Farhad, et al.
Publicado: (2019)

Stricture Following Esophageal Reconstruction
por: Kim, Hyeong Ryul
Publicado: (2020)

Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET
por: Collier, T. Lee, et al.
Publicado: (2017)

Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma
por: Suk, Yujin, et al.
Publicado: (2023)

Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases
por: Zhu, Viola W, et al.
Publicado: (2020)

Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC
por: Zhou, Qing, et al.
Publicado: (2023)

Biodegradable esophageal stents for the treatment of refractory benign esophageal strictures
por: Gkolfakis, Paraskevas, et al.
Publicado: (2020)

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date
por: Akamine, Takaki, et al.
Publicado: (2018)

Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer
por: Katayama, Yuki, et al.
Publicado: (2023)

Foscarnet-Resistant Cytomegalovirus Esophagitis with Stricturing
por: Gaduputi, Vinaya, et al.
Publicado: (2013)

Management of Benign Esophageal Strictures in Children
por: Vandenplas, Yvan
Publicado: (2017)

Acquired noncaustic esophageal strictures in children
por: Sag, Elif, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kn4ona8t3ufqfpu21grajukqf6